Skip to main content
SpringerLink
Log in

Praxisnahe Tipps zu Diagnostik und Therapie

Chronisch entzündliche Darmerkrankungen

A short and pragmatic guide through diagnostics and therapies of chronic inflammatory bowel diseases

  • FORTBILDUNG . ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Zusammenfassung

Die Therapie der chronisch entzündlichen Darmerkrankungen (CED) Morbus Crohn (MC) und Colitis ulcerosa (CU) ist durch den Einsatz von Immunsuppressiva und Antikörpern zwar fundamental effektiver, aber auch anspruchsvoller geworden und daher heute fast ausschließlich in der Hand von CED-Spezialisten. Hausärzte spielen aber eine wichtige Rolle bei der Früherkennung der Erkrankung und der Begleitung der Patienten. Lesen Sie hier einen auf Leitlinien, Studien und Erfahrungswerten basierenden, pragmatischen Überblick über Diagnose und Therapie.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6

Literatur

  1. Colombel JF, Panaccione R, Bossuyt P et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018;390:2779–89.

    Article  Google Scholar 

  2. Darfeuille-Michaud A, Boudeau J, Bulois P et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology. 2004;127:412–21.

    Article  PubMed  Google Scholar 

  3. Tian Z, Liu J, Liao M et al. Beneficial effects of fecal microbiota transplantation on ulcerative colitis in mice. Dig Dis Sci. 2016;61:2262–71.

    Article  PubMed  Google Scholar 

  4. Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989;1:164.

    Article  CAS  PubMed  Google Scholar 

  5. Tao Zuo, Siew C. Ng. The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Front Microbiol. 2018;9:2247.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Rosenstiel P, Sina C, Franke A, Schreiber S. Towards a molecular risk map—recent advances on the etiology of inflammatory bowel disease. Semin Immunol. 2009;21:334–5.

    Article  CAS  PubMed  Google Scholar 

  7. Jostins L, Ripke S, Weersma RK et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Frolkis A, Dieleman LA, Barkema HW et al. Environment and the inflammatory bowel diseases. Can J Gastroenterol. 2013;27:18–24.

    Article  Google Scholar 

  9. Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.

    Article  PubMed  Google Scholar 

  10. Solberg IC, Lygren I, Jahnsen J et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431–40.

    Article  PubMed  Google Scholar 

  11. Faubion WA, Jr, Loftus EV, Jr, Harmsen WS et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.

    Article  CAS  PubMed  Google Scholar 

  12. Michelassi F, Sultan S. Surgical treatment of complex small bowel Crohn disease. Ann Surg. 2014;260:230–5.

    Article  PubMed  Google Scholar 

  13. Henriksen M, Jahnsen J, Lygren I et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543–50.

    Article  PubMed  Google Scholar 

  14. Preiß JC, Bokemeyer B, Buhr HJ et al. Aktualisierte S3-Leitlinie — „Diagnostik und Therapie des Morbus Crohn” 2014. Z Gastroenterol. 2014;52:1431–84.

    Article  PubMed  Google Scholar 

  15. Kucharzik T, Dignass AU, Atreya Raja et al. Aktualisierte S3-Leitlinie Colitis ulcerosa der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol. 2018;56:1087–1169.

    Article  Google Scholar 

  16. Gomollon F, Dignass A, Annese V et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. Journal of Crohn’s and Colitis. 2017;11:3–25.

    Article  PubMed  Google Scholar 

  17. Panes J, Bouzas R, Chaparro M et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther. 2011;34:125–45.

    Article  CAS  PubMed  Google Scholar 

  18. Tillack C, Seiderer J, Brand S et al. Correlation of magnetic resonance enteroclysis (MRE) and wireless capsule endoscopy (CE) in the diagnosis of small bowel lesions in Crohn’s disease. Inflamm Bowel Dis. 2008;14:1219–28.

    Article  PubMed  Google Scholar 

  19. Romkens TE, Kampschreur MT, Drenth JP et al. High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials. Inflamm Bowel Dis. 2012;18:2190–8.

    Article  PubMed  Google Scholar 

  20. Wang Y, Parker CE, Bhanji T et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4:CD000543.

    PubMed  Google Scholar 

  21. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–5.

    Article  CAS  PubMed  Google Scholar 

  22. Williams JG, Alam MF, Alrubaiy L et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016;1:15–24.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Danese S, Fiorino G, Peyrin-Biroulet L et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;20:160:704–11.

    Google Scholar 

  24. Feagan BG, Rutgeerts P, Sands BE et al.: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.

    Article  CAS  PubMed  Google Scholar 

  25. Kotlyar DS, Lewis JD, Beaugerie L et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847–58.

    Article  CAS  PubMed  Google Scholar 

  26. Beigel F, Steinborn A, Schnitzler F et al. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf. 2014;23:735–44.

    Article  CAS  PubMed  Google Scholar 

  27. Qiu Y, Mao R, Chen BL et al. Effects of combination therapy with immunomodulators on trough levels and antibodies against TNF antagonists in patients with Inflammatory Bowel Disease: A Meta-analysis. Clin Gastroenterol Hepatol. 2017;15:1359–72.

    Article  CAS  PubMed  Google Scholar 

  28. Jeong DY, Kim S, Son MJ et al. Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review. Autoimmun Rev. 2019;18:439–54.

    Article  PubMed  Google Scholar 

  29. Sandborn WJ et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017;376:1723–36.

    Article  CAS  PubMed  Google Scholar 

  30. Aschenbrenner D. Tofacitinib trial prompts FDA review of adverse effects. American Journal of Nursing. 2019:119:25.

    Article  PubMed  Google Scholar 

  31. Sands BE, Han C, Zhang Het al. P681 Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies. ECCO abstract P681; 2019.

  32. Ochsenkühn T, Tillack C, Szokodi D et al. One-year experience with ustekinumab in therapy-refractory or -intolerant patients with ulcerative colitis. Journal of Crohn’s and Colitis. 2019;13:298–9.

    Article  Google Scholar 

  33. Lunney PC, Kariyawasam VC, Wang RR et al. Smoking prevalence and its influence on disease course and surgery in Crohn’s disease and ulcerative colitis. Alimentary Pharmacology and Therapeutics. 2015;42:61–70.

    Article  CAS  PubMed  Google Scholar 

  34. Hanauer SB, Sandborn WJ, Feagan BG et al. IM-UNITI: 3 year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn’s disease. J Crohns Colitis. 2019; pii: jjz110. doi: https://doi.org/10.1093/ecco-jcc/jjz110. [Epub ahead of print]

  35. Mantzaris GJ. Thiopurines and methotrexate use in IBD patients in a biologic era. Curr Treat Options Gastroenterol 2017;15:84–104.

    Article  PubMed  Google Scholar 

  36. Jørgensen KK, Olsen IC, Goll GL et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304–16.

    Article  PubMed  Google Scholar 

  37. Ye BD, Pesegova M, Alexeeva O et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393:1699–1707.

    Article  CAS  PubMed  Google Scholar 

  38. Gecse KB, Végh Z, Lakatos PL. Optimizing biological therapy in Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2016;10:37–45.

    Article  CAS  PubMed  Google Scholar 

  39. Allen PB, Olivera P, Emery P et al. Review article: moving towards common therapeutic goals in Crohn’s disease and rheumatoid arthritis. Aliment Pharmacol Ther. 2017;45:1058–72.

    Article  CAS  PubMed  Google Scholar 

  40. Parragi L, Fournier N, Zeitz J et al. Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. J Crohns Colitis 2018;12:811–18.

    Article  PubMed  Google Scholar 

  41. Jürgens M, Laubender RP, Hartl F et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811–9.

    Article  PubMed  CAS  Google Scholar 

  42. Braun I, Heitland W, Bader F et al. Einfluss des präoperativen Einsatzes von TNF-alpha-Antikörpern auf den peri- und postoperativen Verlauf von CED-Patienten mit Darmresektionen. Z Gastroenterol. 2018;56:e215–6.

    Google Scholar 

  43. Lightner AL, McKenna NP, Alsughayer A et al. Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn’s patients. Pediatr Surg. 2019; S0022-3468(19)30015-6. doi: https://doi.org/10.1016/j.jpedsurg.2019.01.006. [Epub ahead of print].

    Article  PubMed  Google Scholar 

  44. Xu Y, Yang L, An P et al. Meta-Analysis: The influence of preoperative infliximab use on postoperative complications of Crohn’s Disease. Inflamm Bowel Dis. 2019;25:261–9.

    Article  PubMed  Google Scholar 

  45. Brennan GT, Ha I, Hogan C et al. Does preoperative enteral or parenteral nutrition reduce postoperative complications in Crohn’s disease patients: a meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:997–1002.

    Article  PubMed  Google Scholar 

  46. Lichtiger S, Present DH. Preliminary report: Cyclosporin in treatment of severe active ulcerative colitis. Lancet;1990;226:16–9.

    Article  Google Scholar 

  47. Herrmann KA, Michaely HJ, Seiderer J, Ochsenkuehn T et al. The „star-sign“ in magnetic resonance enteroclysis: a characteristic finding of internal fistulae in Crohn’s disease. Scand J Gastroenterol. 2006;41:239–41.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Crohn- und Colitis-Zentrum München, Sonnenstraße 29, D-80331, München, Deutschland

    Thomas Ochsenkühn,  Daniel Szokodi &  Cornelia Tillack

Authors
  1. Thomas Ochsenkühn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Szokodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cornelia Tillack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Ochsenkühn.

Additional information

This article is part of a supplement not sponsored by the industry.

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: Prof. Ochsenkühn (Honorare für Vorträge, Studien und Beratungen sowie Reisekostenunterstützungen für Kongressteilnahmen von folgenden Firmen: Abbvie, Amgen, Biogen, Celltrion, Janssen, MSD, Pfizer, Sandoz, Takeda); Dr. Szokodi (Aufwendungen durch die Firmen MSD, Pfizer, Shire und Janssen), Dr. Tillack (Vortrags-, Forschuns- und Beratertätigkeit für die Firmen MSD, Pfizer, Janssen und Abbott.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ochsenkühn, T., Szokodi, D. & Tillack, C. Chronisch entzündliche Darmerkrankungen. MMW - Fortschritte der Medizin 161 (Suppl 3), 52–60 (2019). https://doi.org/10.1007/s15006-019-0857-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-019-0857-1

Keywords

Search

Navigation